NEW YORK (GenomeWeb) – LifeLabs and GenXys Health Care Systems announced today that they have formed a partnership to offer pharmacogenetic testing services in Canada.
LifeLabs will analyze patient-submitted cheek swab samples to looks for 60 genetic variations that can affect drug metabolism and response. Those results will then be added to GenXys' TreatGxPlus software, which integrates a patient's pharmacogenetic data with information such as age, weight, blood pressure, allergies, other medical conditions, or medications the patient might be taking.
TreatGxPlus combs through the latest reliable evidence about the safety and effectiveness of more than 750 drugs to help doctors make treatment decisions based on the patient's pharmacogenetic and non-genetic information. The software includes evidence for medications used to treat more than 30 of the most common conditions, such as depression, hypertension, and osteoarthritis, GenXys said.
"Advancements in technology allow us to provide services and information specifically tailored to the unique characteristics of every patient," LifeLabs CEO Sue Paish said in a statement. "Partnering with GenXys positions Canada as a leader in personalized medicine and gives Canadians and their healthcare providers more confidence in the effectiveness of their medical treatment, putting less strain on our health care system."